Home

Insmed Incorporated - Common Stock (INSM)

130.00
+2.20 (1.72%)
NASDAQ · Last Trade: Aug 18th, 12:33 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close127.80
Open127.80
Bid129.76
Ask130.09
Day's Range127.54 - 130.13
52 Week Range60.40 - 128.48
Volume978,716
Market Cap14.98B
PE Ratio (TTM)-22.85
EPS (TTM)-5.7
Dividend & YieldN/A (N/A)
1 Month Average Volume2,962,740

Chart

About Insmed Incorporated - Common Stock (INSM)

Insmed Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious and rare diseases. The company specializes in creating treatments for conditions related to severe respiratory infections, particularly those caused by non-tuberculous mycobacteria. Insmed’s research and development efforts are driven by a commitment to address unmet medical needs, utilizing advanced science and technology to bring forward new options for patients who often have limited alternatives. Through their clinical programs, Insmed aims to improve health outcomes and enhance the quality of life for individuals suffering from these challenging conditions. Read More

News & Press Releases

Intel, UnitedHealth, And Reddit Are Among Top Large Cap Gainers Last Week (August 11-August 15): Are The Others In Your Portfolio?benzinga.com
These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.
Via Benzinga · August 17, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 14, 2025
Assessing Insmed: Insights From 20 Financial Analystsbenzinga.com
Via Benzinga · August 13, 2025
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Weekstocktwits.com
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
Via Stocktwits · August 13, 2025
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Diseasestocktwits.com
Via Stocktwits · August 12, 2025
Earnings Scheduled For August 7, 2025benzinga.com
Via Benzinga · August 7, 2025
What Does the Market Think About Insmed?benzinga.com
Via Benzinga · June 19, 2025
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · August 13, 2025
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstaticstocktwits.com
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.
Via Stocktwits · August 13, 2025
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Diseasebenzinga.com
The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.
Via Benzinga · August 12, 2025
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approvalinvestors.com
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.
Via Investor's Business Daily · August 12, 2025
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · August 7, 2025
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
NetworkNewsWire Editorial Coverage : As America’s population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration’s “Make America Healthy Again” initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is making strides with its HyBryte(“TM”) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (“CTCL”), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte’s active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…
Via Investor Brand Network · August 4, 2025
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END
Via FinancialNewsMedia · August 4, 2025
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?investors.com
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.
Via Investor's Business Daily · July 24, 2025
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'benzinga.com
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
Via Benzinga · July 10, 2025
A Glimpse Into The Expert Outlook On Insmed Through 12 Analystsbenzinga.com
Via Benzinga · July 8, 2025
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · July 2, 2025
Russell Rebalance: 3 Stocks Ready to Move Higher
The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000
Via MarketBeat · June 20, 2025
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?benzinga.com
Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them?
Via Benzinga · June 15, 2025
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · June 11, 2025
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecastbenzinga.com
BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.
Via Benzinga · June 11, 2025
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · June 11, 2025
Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings)benzinga.com
Via Benzinga · June 10, 2025
Dow Gains 50 Points; US Small Business Optimism Index Rises In Maybenzinga.com
Via Benzinga · June 10, 2025